2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3983 Initial results for use of pomalidomide as maintenance after CAR-T therapy in patients with relapsed/ refractory myeloma.

Nishi Shah, MD, MPH, Richa Parikh, MD2, Nisha Joseph, MD3, Craig Hofmeister, MD, MPH4, Sara Scott5, Danielle Roberts, MD6, Vikas Gupta, MD, PhD7, Jonathan L Kaufman, MD8, Roberto Mina9, Ajay K Nooka, MD, MPH10, Sagar Lonial, MD, FACP11
1 Winship Cancer Institute, Atlanta, Georgia
2 Winship Cancer Institute, Atlanta, Georgia
3 Winship Cancer Institute, Atlanta, Georgia
4 Winship Cancer Institute, Atlanta, Georgia
5 Winship Cancer Institute, Atlanta, Georgia
6 Winship Cancer Institute, Atlanta, Georgia
7 Winship Cancer Institute, Atlanta, Georgia
8 Winship Cancer Institute, Atlanta, Georgia
9 Winship Cancer Institute, Atlanta, Georgia
10 Winship Cancer Institute, Atlanta, Georgia
11 Winship Cancer Institute, Atlanta, Georgia

Carvykti, a BCMA directed CAR-T cell therapy is increasingly being used for relapsed/refractory MM. Unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. However, there are emerging reports that suggest use of IMIDs or Celmods could potentially improve T-cell fitness.

The aim of this retrospective analysis is to evaluate the safety and toxicity of pomalidomide as maintenance in multiple myeloma patients who have received carvykti as standard of care at Winship Cancer institute. The patients were started on pomalidomide at the discretion of treating oncologist. For patients with ongoing cytopenia, pomalidomide was deferred. Pomalidomide was started at month 3 and continued until 1 year post CAR-T.

Between 8/2022 to 5/4/2026, 238 patients received Carvykti commercially. Of the total 238 patients who received carvykti, 107 (45%) were females. 52.9% were whites, 42.8% were African American.  Median age at the time of Carvykti infusion was 65 years (Range 38-85 years) Pomalidomide was initiated as maintenance therapy in 45 patients. 5 could not tolerate it due to cytopenia, pneumonitis or drug rash. 40 patients (16.8%) have been started on pomalidomide from day 90 with the intent to  continue until 1 year post CAR-T. Median follow-up for the entire cohort is 375 days( 19-1253 days)

Median PFS is 1060 days ( 95% CI 875-1110 days). Median PFS is not statistically different for patients based on use of pomalidomide maintenance. Out of 238 patients, immune mediated events were observed in 32 patients (13.4%). Amongst patients on pomalidomide maintenance, immune mediated events were seen in 3 patients (7.5%). Secondary malignancies were seen in 13 patients (5.4%). In patients on pomalidomide maintenance, secondary cancers were seen in 4 patients (10%).

Long term follow-up will be crucial to understand the impact of pomalidomide on PFS. Updated results will be presented at ASH. Based on the current results, pomalidomide as maintenance therapy appears safe. Long term follow-up of these patients will provide valuable information on the effectiveness of this drug as maintenance therapy.

Nishi Shah, MD, MPH: Clinical trial -IGI, MMRC - Research Funding